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evidence-based guidelines from 1998 also recom-
mend MDI/S for children aged >1 year with acute
asthma exacerbations.9 This guideline suggests
using 4 to 8 puffs from a 90 µg albuterol MDI at
1- to 2-minute intervals every 20 minutes for 1
hour, then every 1 to 4 hours subsequently.
Julian T. Hsu, MD, Sandi Parker, MLIS,
University of Colorado Health Sciences Center, Denver
■ CLINICAL COMMENTARY
Use MDIs with spacers 
in all but the youngest patients
Until recently, using a nebulizer for the wheez-
ing child or infant seemed intuitively to be the
most effective way to deliver bronchodilators.
However, with recent data showing that MDIs
with spacers are just as effective, I have been
using MDIs with spacers for all but my
youngest patients. Parents as well as physi-
cians may need to be convinced that using less
technology in this case is better for their child.
In some cases, parental acceptance of therapy
necessitates using a nebulizer. 
Grant Hoekzema, MD, Mercy Family Medicine
Residency, St. Louis, Mo
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Do antipyretics 
prolong febrile illness?
■ EVIDENCE-BASED ANSWER
Antipyretics appear to have minor and variable
effects on the course of febrile illness. Aspirin and
acetaminophen do not prolong the course of rhi-
novirus illness, although they may prolong the
period of viral shedding and worsen nasal conges-
tion (strength of recommendation [SOR]: A–,
based on small randomized controlled trials). 
Acetaminophen did not affect symptoms, over-
all condition, or time to complete healing in chil-
dren with varicella, although it increased the time
to total scabbing of lesions (SOR: A, based on a
small randomized controlled trial). Aspirin and
acetaminophen may prolong influenza A illness
(SOR: C, based on a poor-quality, retrospective
observational study). 
Acetaminophen may prolong the course of
Shigella sonnei infection (SOR: B–, based on a
small retrospective cohort study). It does not
affect malaria cure rate, and there are insufficient
data to assess clearance of Plasmodium falciparum
(SOR: C, based on small randomized controlled
trials with heterogeneous results).  
■ EVIDENCE SUMMARY
Acetaminophen has a different mechanism of
action from other antipyretics. It halts the 
production of prostaglandin in the brain but not in
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the periphery, solely lowering fever. Aspirin and
other nonsteroidal anti-inflammatory agents
inhibit both central and peripheral cyclooxyge-
nase and may cause multiple effects in addition to
temperature reduction. Clinical outcome studies
of their antipyretic effects are inconclusive.1
A randomized controlled trial involving 60 
volunteers given intranasal rhinovirus type 2
monitored the effect of aspirin, acetaminophen,
ibuprofen, or placebo on virus shedding, immune
response, and clinical status. There was no differ-
ence in duration of illness. There was a trend
toward longer duration of virus shedding in the
aspirin and acetaminophen groups, but serum
neutralizing antibody response was suppressed
(P<.05 vs placebo). Aspirin and acetaminophen
worsened symptoms of turbinate edema and nasal
obstruction (P<.05 vs placebo).2
In 2 double-blind trials, 45 adults infected with
rhinovirus were given aspirin or placebo for 5
days, beginning on the day after viral exposure (as
opposed to the typical use in response to symp-
toms). Aspirin treatment improved symptoms of
conjunctivitis significantly, but did not change the
duration of illness. Other symptoms (headache,
sneezing, chills, malaise, nasal discharge) were
not significantly different. Aspirin increased the
amount of viral shedding by 36% in 1 trial and
17% in the other (P<.01), potentially increasing
risk of spread.3
In a randomized controlled trial evaluating
antipyretic effects on the duration or severity of
childhood varicella, 31 children received placebo
and 37 received acetaminophen for 4 days. There
was no difference in itching, appetite, activity, or
overall condition between the 2 groups. Children
treated with acetaminophen took 1.1 days longer
to total scabbing (P<.05), although the number of
days until the appearance of the last new vesicle
and the time to total healing were unchanged. The
duration of viral shedding was not measured, but
it is possible that the delay in healing of lesions
would prolong viral shedding as well.4
A retrospective observational study of 54 
volunteers demonstrated prolonged illness in sub-
jects infected with influenza A that received
antipyretic therapy. Patients who got antipyretics
were sick 3.5 days longer than those who did not
(8.8 ± 2.3 days vs 5.3 ± 3.0 days; P<.001). Only
patients with temperatures >38.9°C on 2 readings
6 hours apart received antipyretics, indicating
that the longer course correlated with greater
severity of illness as well as with antipyretic use. 
In the same study, antipyretics were associat-
ed with a trend towards prolonged duration of 
illness in a group of 21 patients infected with 
S sonnei (4.6 ± 2.1 days with antipyretics vs 1.9 ±
1.6 days without; P=not significant).5
A Cochrane review examined 3 trials of aceta-
minophen vs placebo for fever in 128 adults and
children with P falciparum malaria. Although
fever clearance varied between the trials, the
malaria cure rate was similar in all, and the
review concluded that data were insufficient to
evaluate an effect on parasitemia.6
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What are Clinical Inquiries?
Clinical Inquiries answer real questions that family physi-
cians submit to the Family Practice Inquiries Network (FPIN),
a national, not-for-profit consortium of family practice depart-
ments, residency programs, academic health sciences
libraries, primary care practice-based research networks,
and other specialists.
Questions chosen are those family physicians vote as most
important through a web-based voting system.
Answers are developed by a specific method:
• FPIN medical librarians conduct systematic and 
standardized literature searches in collaboration with an
FPIN clinician or clinicians.
• FPIN clinician authors select the research articles to
include, critically appraise the research evidence, review
the authoritative sources, and write the answers.
• Each Clinical Inquiry is reviewed by 4 or more peers and
editors before publication in JFP.
• FPIN medical librarians co-author each of the Clinical
Inquiries that have required a systematic search.
• Finally, a practicing family physician writes an
accompanying commentary.
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■ RECOMMENDATIONS FROM OTHERS
We found no recommendations regarding the use
of antipyretics and their effect on the duration of
febrile illness.
Laura Hudgings, MD, Gary Kelsberg, MD, Valley
Family Care Family Medicine Residency, Renton, Wash;
Sarah Safranek, MLIS, University of Washington
Health Sciences Library, Seattle
■ CLINICAL COMMENTARY
The risk-benefit ratio of antipyretics 
may not be as favorable as you think
The doctor’s recommendation, “Take two
aspirin and call me in the morning,” is an
enduring stereotype, not an evidence-based
therapy for a fever. This review reevaluates
the simplistic notion that antipyretics are uni-
formly beneficial and safe in febrile illnesses.
Surprisingly, there appear to be some nega-
tive impacts from using antipyretics for com-
mon disease states without much clear bene-
fit. It can be argued that the studies are small
and purported negative consequences modest.
Still, enough evidence exists to warrant more
research and to cause clinicians to consider
that the risk-to-benefit ratio of these medica-
tions may not be as favorable as once thought.
Jon O. Neher, MD, Valley Medical Center Family
Medicine Residency
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Is folate supplementation
indicated for patients 
with CAD?
■ EVIDENCE-BASED ANSWER
There is insufficient evidence to advocate the 
routine use of folate supplementation for the
treatment of coronary artery disease (CAD). High
levels of serum homocysteine have been associated
in several studies with an increased risk for CAD
(strength of recommendation [SOR]: B, associat-
ed in case-control studies). Folate supplementa-
tion decreases the level of serum homocysteine
(SOR: A, meta-analysis of randomized controlled
trials). This indirect evidence suggests that folate
supplementation may be of benefit in slowing the
progress of arteriosclerosis. 
Two randomized controlled trials measuring
the clinical benefits of folate supplementation for
patients with CAD have been completed, with 
differing results. One study showed no benefit of
0.5 mg/d of folate for patients with stable CAD
already on statin therapy. The other study found
that patients given 1 mg/d of folate with vitamins
B6 and B12 had a decreased restenosis rate after
percutaneous coronary intervention (PCI) (SOR:
B, conflicting randomized controlled trials).
It is possible that larger doses of folate are
needed to be of clinical benefit, or that the addi-
tion of vitamins B6 and B12 are needed for synergy.
Several randomized control trials are underway to
further assess folate’s affect on CAD. 
■ EVIDENCE SUMMARY
Hyperhomocysteinemia is defined as a fasting
plasma homocysteine level 15 µmol/L, although
levels >10 µmol/L appear to have detrimental
effects on risk profiles for CAD and arteriosclero-
sis.1 In 22 of 27 retrospective case-control studies,
patients with CAD had significantly higher 
plasma homocysteine levels than control subjects
(odds ratio [OR]=1.2–10.9, after adjustment for
other CAD risk factors).2,3 However, only 4 of 7
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